Wegovy 2.7mg — Does This Dose Exist, and What Should You Know?

Where the 2.7mg figure comes from, and what it actually means on a Wegovy pen

One of the most common questions our prescribers encounter is why patients have seen "2.7" printed on their Wegovy pen or packaging. The short answer is that it describes millilitres, not milligrams. Each Wegovy pen contains 2.7ml of solution regardless of the strength selected, the concentration of semaglutide within that fluid is what changes between doses. A 0.25mg pen and a 2.4mg pen hold the same liquid volume; the active medicine per dose is simply more concentrated at higher strengths.

This matters because patients sometimes worry they've received a non-standard product, or wonder whether 2.7mg sits somewhere between 2.4mg and the recently approved 7.2mg strength. It doesn't. The NHS patient information on semaglutide confirms the five-step licensed schedule clearly, and the 2.7ml cartridge figure is a pharmaceutical detail, not a clinical target. If the label on your pen looks unfamiliar, you can listen to our prescribers discuss exactly this kind of confusion in our podcast covering Wegovy dosing and patient questions, or raise it with your prescribing team before your next injection.

You can read the NHS's overview of semaglutide, including Wegovy's licensed strengths, for a clear breakdown of what each dose step involves.

How the Wegovy titration schedule actually works, from starter dose to maintenance

Wegovy treatment opens at 0.25mg weekly for four weeks. This isn't the therapeutic target; it's a settling-in period designed to let the body adjust to the medicine and limit early gastrointestinal discomfort. After four weeks a prescriber typically steps the dose to 0.5mg, then 1.0mg, then 1.7mg, and finally to the 2.4mg maintenance dose, each step roughly four weeks apart.

Trial data underpins this approach. In the STEP 1 study, published in the New England Journal of Medicine, adults without diabetes who reached the 2.4mg maintenance dose saw an average body-weight reduction of around 15% over 68 weeks alongside lifestyle support. That evidence base is the reason NICE, in its guidance on semaglutide for weight management, set 2.4mg as the licensed maintenance target rather than any intermediate figure, and our dedicated page on Wegovy 2 covers the clinical context around that maintenance threshold in more detail. The full Wegovy treatment overview covers this context in more detail.

Each step-up is a clinical decision. A prescriber may recommend staying at a lower dose for longer if side effects are significant, or may reach 2.4mg on the standard timeline if tolerance is good. There is no therapeutic benefit to skipping steps, the stepped schedule exists precisely because it improves tolerability without compromising the eventual outcome.

What the newer 7.2mg approval changes, and what it doesn't

On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, following the earlier January 2026 approval of the 7.2mg dose itself. This higher strength is licensed for adults with a BMI of 30 or above, the cardiovascular-risk indication is excluded at this dose level. In trials, 7.2mg produced average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide at its highest strength, and you can read a full breakdown of what that development means for patients on our Wegovy 2.0 page.

The approval is confirmed on the GOV.UK announcement from April 2026. Crucially, the titration pathway to 7.2mg still begins at 0.25mg, patients don't start at a high dose. Whether the 7.2mg pen is the right option for a given individual is, again, a prescriber's call, made on the basis of clinical review.

For those researching the routes to accessing Wegovy in the UK, it's worth knowing that dose availability is confirmed at consultation, not before, any pharmacy or clinic that guarantees a specific strength before your assessment has skipped the step that makes the selection safe.

Eligibility, clinical oversight, and next steps

Under its UK licence, Wegovy is suitable for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds, in line with UK clinical guidance. These criteria are a starting point, the full picture includes medical history, current medicines, and any contraindications, all of which a prescriber reviews before any dose is issued.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it's submitted, a real clinician, not an automated filter. If you're curious about how the clinical process works or want to understand what's assessed, our about us page explains the clinical structure, and you can verify our pharmacy on the GPhC register (registration number 9012878). For a broader picture of how Wegovy sits alongside other licensed options, our weight-loss treatment overview is a useful starting point. Those interested in what the evidence says about semaglutide more broadly will find the detail on the semaglutide information page.

If you're ready to find out whether you're eligible, check your eligibility with a free consultation, the process takes a few minutes and is reviewed the same working day.